HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway.

Abstract
The mevalonate pathway is an important drug target for the treatment of cancer and cardiovascular disease. We synthesized and studied a new type of nitrogen-containing bisphosphonate analogs and developed a sensitive end point assay method for enzyme FPPS, which was used for inhibitor screening. One potent FPPS inhibitor was discovered, and the structure-activity relationship of bisphosphonates for the enzyme inactivation was studied.
AuthorsJinbo Gao, Xiusheng Chu, Yongge Qiu, Long Wu, Yuqin Qiao, Jiasheng Wu, Ding Li
JournalChemical communications (Cambridge, England) (Chem Commun (Camb)) Vol. 46 Issue 29 Pg. 5340-2 (Aug 7 2010) ISSN: 1364-548X [Electronic] England
PMID20544107 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Alkyl and Aryl Transferases
  • Mevalonic Acid
Topics
  • Alkyl and Aryl Transferases (antagonists & inhibitors)
  • Biocatalysis
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Inhibitory Concentration 50
  • Mevalonic Acid (metabolism)
  • Molecular Structure
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: